154 related articles for article (PubMed ID: 35948477)
41. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
Niitsu N; Okamoto M; Tomita N; Aoki S; Tamaru J; Miura I; Hirano M
Leuk Lymphoma; 2006 Sep; 47(9):1908-14. PubMed ID: 17065005
[TBL] [Abstract][Full Text] [Related]
42. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
[TBL] [Abstract][Full Text] [Related]
43. Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease.
Keskin EY; Gursel T; Uluoglu O; Albayrak M; Kaya Z; Coskun U; Kocak U
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e294-6. PubMed ID: 20736843
[TBL] [Abstract][Full Text] [Related]
44. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
Bujan L; Walschaerts M; Brugnon F; Daudin M; Berthaut I; Auger J; Saias J; Szerman E; Moinard N; Rives N; Hennebicq S
Fertil Steril; 2014 Sep; 102(3):667-674.e3. PubMed ID: 25044088
[TBL] [Abstract][Full Text] [Related]
45. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
46. The impact of conventional and high-dose therapy for lymphoma on fertility.
Grigg A
Clin Lymphoma; 2004 Sep; 5(2):84-8. PubMed ID: 15453922
[TBL] [Abstract][Full Text] [Related]
47. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Johnson PW
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):316-322. PubMed ID: 27913497
[TBL] [Abstract][Full Text] [Related]
48. Trials in advanced Hodgkin's disease: more than 30 years experience of the British National Lymphoma Investigation.
Zekri JM; Mouncey P; Hancock BW
Clin Lymphoma; 2004 Dec; 5(3):174-83. PubMed ID: 15636693
[TBL] [Abstract][Full Text] [Related]
49. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
50. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
51. [Pathological characteristics and clinical prognosis of nodular sclerosis grade 2 of classic Hodgkin's lymphoma].
Xue XM; Cao Z; Yuan T; Luo YY; Mu JL; Qin Y; Feng XL
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):581-586. PubMed ID: 35754234
[No Abstract] [Full Text] [Related]
52. Hodgkin's lymphoma--the great teacher.
Connors JM
N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
[No Abstract] [Full Text] [Related]
53. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
54. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.
Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M
Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154
[TBL] [Abstract][Full Text] [Related]
55. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.
Franklin J; Diehl V
Ann Oncol; 2002; 13 Suppl 1():98-101. PubMed ID: 12078913
[TBL] [Abstract][Full Text] [Related]
56. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz MZ; Horning SJ; Balise R; Greenberg PL; Rosenberg SA; Hoppe RT; Advani RH
J Clin Oncol; 2013 Feb; 31(5):592-8. PubMed ID: 23295809
[TBL] [Abstract][Full Text] [Related]
57. [Cytostatic chemotherapy of lymphogranulomatosis].
Dold U
Dtsch Med Wochenschr; 1978 Feb; 103(6):235-8. PubMed ID: 75085
[No Abstract] [Full Text] [Related]
58. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
59. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Chisesi T; Federico M; Levis A; Deliliers GL; Gobbi PG; Santini G; Luminari S; Linfomi MB;
Ann Oncol; 2002; 13 Suppl 1():102-6. PubMed ID: 12078888
[TBL] [Abstract][Full Text] [Related]
60. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
Santoro A; Bonadonna G
Cancer Chemother Pharmacol; 1979; 2(2):101-5. PubMed ID: 93984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
